Francolini, G., Cataldo, V. D., Garlatti, P., Caini, S., Bruni, A., Simoni, N., Augugliaro, M., Iacovelli, R., Ciccarese, C., Tagliaferri, L., Battelli, N., Ingrosso, G., Porreca, A., Vullo, G., Fornarini, G., Iorio, G. C., Guarneri, A., Sisani, M., Grazia, A. D., Livi, L. (2026). PERSIAN trial (NCT03449719): Predictive features of complete biochemical response within a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.157